A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors

Recruiting now · Phase 1

Conditions studied: Advanced Malignant Solid Tumor

In brief

VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2025, and recommended dose of VG2025 for Phase II trials.

Key facts

Study ID

NCT05477849

Run by

Shanghai Virogin Biotech Co., Ltd.

People needed

30

Starts

2022-08-23

Expected to finish

2025-12-31

Last updated by the study team

2025-04-01

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed written informed consent form.
• Age 18 to 75 years (inclusive), male or female.
• Subject with advanced malignant solid tumors who have failed standard treatment and for whom there is no effective treatment at this stage.
• Eligible patients of childbearing potential (male and female) must agree to use a reliable method of contraception during the trial and for at least 90 days after dosing; females of childbearing potential must have a negative blood pregnancy test 7 days before enrollment.

You may not qualify if…

• Subjects who have received other unlisted drugs clinical trial treatment 4 weeks before the first dose of the study drug.
• Subjects who underwent major organ surgery (excluding needle biopsy) or had significant trauma 4 weeks before the first dose of the study drug.
• In the herpes simplex virus recurrence and infection period, and there are corresponding clinical manifestations, such as oral herpes labialis, herpetic keratitis, herpetic dermatitis, genital herpes and so on.
• Other active uncontrolled infection.
• Known alcohol or drug dependence.
• Subjects with mental disorders or poor compliance.
• Women who are pregnant or breastfeeding.
• Subjects in the opinion of the investigator are not suitable for this clinical study due to other serious systemic diseases or other reasons.

Where it is running

• The First Affiliated Hospital，Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.